Activity of newest generation β-lactam/β-lactamase inhibitor combination therapies against multidrug resistant pseudomonas aeruginosa

HIGHLIGHTS

• who: Robbie R. Haines from the SchoolThe University Nedlands, WA, Australia have published the research work: Activity of newest generation u03b2-lactam/u03b2-lactamase inhibitor combination therapies against multidrug resistant Pseudomonas aeruginosa, in the Journal: Scientific Reports Scientific Reports
• what: The authors determined the MIC of I-R, CZA, and C/T against MDR CFPA isolates. Whilst this study provides important in_vitro data supporting the clinical use of new combinations, it is important that the potential for MDR CFPA to develop resistance to these combinations also be evaluated. Studies examining the propensity for organisms to . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.